Treatment of primary Sjögren syndrome: a systematic review.

CONTEXT A variety of topical and systemic drugs are available to treat primary Sjögren syndrome, although no evidence-based therapeutic guidelines are currently available. OBJECTIVE To summarize evidence on primary Sjögren syndrome drug therapy from randomized controlled trials. DATA SOURCES We searched MEDLINE and EMBASE for articles on drug therapy for primary Sjögren syndrome published between January 1, 1986, and April 30, 2010. STUDY SELECTION Controlled trials of topical and systemic drugs including adult patients with primary Sjögren syndrome were selected as the primary information source. RESULTS The search strategy yielded 37 trials. A placebo-controlled trial found significant improvement in the Schirmer and corneal staining scores, blurred vision, and artificial tear use in patients treated with topical ocular 0.05% cyclosporine. Three placebo-controlled trials found that pilocarpine was associated with improvements in dry mouth (61%-70% vs 24%-31% in the placebo group) and dry eye (42%-53% vs 26%). Two placebo-controlled trials found that cevimeline was associated with improvement in dry mouth (66%-76% vs 35%-37% in the placebo group) and dry eye (39%-72% vs 24%-30%). Small trials (<20 patients) found no significant improvement in sicca outcomes for oral prednisone or hydroxychloroquine and limited benefits for immunosuppressive agents (azathioprine and cyclosporine). A large trial found limited benefits for oral interferon alfa-2a. Two placebo-controlled trials of infliximab and etanercept did not achieve the primary outcome (a composite visual analog scale measuring joint pain, fatigue, and dryness); neither did 2 small trials (<30 patients) testing rituximab, although significant results were observed in some secondary outcomes and improvement compared with baseline. CONCLUSIONS In primary Sjögren syndrome, evidence from controlled trials suggests benefits for pilocarpine and cevimeline for sicca features and topical cyclosporine for moderate or severe dry eye. Anti-tumor necrosis factor agents have not shown clinical efficacy, and larger controlled trials are needed to establish the efficacy of rituximab.

[1]  A. Sisó-Almirall,et al.  Primary Sjögren syndrome , 2012, BMJ : British Medical Journal.

[2]  E. de Ramón,et al.  Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases. , 2010, Clinical and experimental rheumatology.

[3]  A. Vissink,et al.  Effectiveness of rituximab treatment in primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled trial. , 2010, Arthritis and rheumatism.

[4]  E. Toker,et al.  Corneal and Conjunctival Sensitivity in Patients With Dry Eye: The Effect of Topical Cyclosporine Therapy , 2010, Cornea.

[5]  Y. Konttinen,et al.  Dehydroepiandrosterone (DHEA) substitution treatment for severe fatigue in DHEA‐deficient patients with primary Sjögren's Syndrome , 2010, Arthritis care & research.

[6]  A. Vissink,et al.  Clinical and histologic evidence of salivary gland restoration supports the efficacy of rituximab treatment in Sjögren's syndrome. , 2009, Arthritis and rheumatism.

[7]  T. Witte,et al.  Treatment of sicca symptoms with hydroxychloroquine in patients with Sjogren's syndrome. , 2009, Rheumatology.

[8]  G. Baron,et al.  EULAR Sjögren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjögren's syndrome , 2009, Annals of the rheumatic diseases.

[9]  C. Ohlsson,et al.  Low serum levels of sex steroids are associated with disease characteristics in primary Sjogren's syndrome; supplementation with dehydroepiandrosterone restores the concentrations. , 2009, The Journal of clinical endocrinology and metabolism.

[10]  M. Takei,et al.  Efficacy and safety of rebamipide for the treatment of dry mouth symptoms in patients with Sjögren’s syndrome: a double-blind placebo-controlled multicenter trial , 2009, Modern rheumatology.

[11]  Jun-Sub Choi,et al.  A comparison of vitamin a and cyclosporine a 0.05% eye drops for treatment of dry eye syndrome. , 2009, American journal of ophthalmology.

[12]  M. Ramos-Casals,et al.  A Systematic Review of the Off-Label Use of Biological Therapies in Systemic Autoimmune Diseases , 2008, Medicine.

[13]  J. Jiménez-Alonso,et al.  Primary Sjögren Syndrome in Spain: Clinical and Immunologic Expression in 1010 Patients , 2008, Medicine.

[14]  T. Kasama,et al.  Effect of the H2 receptor antagonist nizatidine on xerostomia in patients with primary Sjögren’s syndrome , 2008, Modern rheumatology.

[15]  W. Leung,et al.  The efficacy of cevimeline hydrochloride in the treatment of xerostomia in Sjögren’s syndrome in southern Chinese patients: a randomised double-blind, placebo-controlled crossover study , 2008, Clinical Rheumatology.

[16]  P. Emery,et al.  Reduction of fatigue in Sjögren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study , 2008, Annals of the rheumatic diseases.

[17]  S. Gabriel,et al.  Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. , 2008, Arthritis and rheumatism.

[18]  T. Salo,et al.  Effectiveness of low-dose doxycycline (LDD) on clinical symptoms of Sjögren's Syndrome: a randomized, double-blind, placebo controlled cross-over study , 2007, Journal of Negative Results in BioMedicine.

[19]  T. Mimori,et al.  Efficacy and safety of mizoribine for the treatment of Sjögren's syndrome: a multicenter open-label clinical trial , 2007, Modern rheumatology.

[20]  M. Gaubitz,et al.  Mycophenolate sodium treatment in patients with primary Sjögren syndrome: a pilot trial , 2007, Arthritis research & therapy.

[21]  B. Cochener,et al.  Ultrasound assessment of salivary glands in patients with primary Sjögren’s syndrome treated with rituximab: Quantitative and Doppler waveform analysis , 2007, Biologics : targets & therapy.

[22]  C. Roberts,et al.  Comparison of Topical Cyclosporine, Punctal Occlusion, and a Combination for the Treatment of Dry Eye , 2007, Cornea.

[23]  R. Geenen,et al.  Effect of dehydroepiandrosterone administration on fatigue, well-being, and functioning in women with primary Sjögren syndrome: a randomised controlled trial , 2007, Annals of the rheumatic diseases.

[24]  J. Pers,et al.  BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjögren's syndrome. , 2007, Arthritis and rheumatism.

[25]  B. Cochener,et al.  Improvement of Sjögren's syndrome after two infusions of rituximab (anti-CD20). , 2007, Arthritis and rheumatism.

[26]  Terry Kim,et al.  Recurrence after topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjögren's syndrome. , 2007, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[27]  T. Sumida,et al.  Efficacy prediction of cevimeline in patients with Sjögren’s syndrome , 2007, Clinical Rheumatology.

[28]  R. Geenen,et al.  Safety and efficacy of leflunomide in primary Sjögren’s syndrome: a phase II pilot study , 2007, Annals of the rheumatic diseases.

[29]  Cheng-Han Wu,et al.  Pilocarpine Hydrochloride for the Treatment of Xerostomia in Patients with Sjögren's Syndrome in Taiwan—A Double-blind, Placebo-controlled Trial , 2006, Journal of the Formosan Medical Association.

[30]  X. Mariette,et al.  Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren’s syndrome , 2006, Annals of the rheumatic diseases.

[31]  G. Burmester,et al.  Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II study , 2006, Arthritis research & therapy.

[32]  A. Vissink,et al.  Progression of salivary gland dysfunction in patients with Sjögren’s syndrome , 2006, Annals of the rheumatic diseases.

[33]  Stephen Cohen,et al.  An Evaluation of the Efficacy of a Cyclosporine-Based Dry Eye Therapy When Used With Marketed Artificial Tears as Supportive Therapy in Dry Eye , 2006, Eye & contact lens.

[34]  S. Pflugfelder,et al.  Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years. , 2005, Ophthalmology.

[35]  A. Vissink,et al.  Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study. , 2005, Arthritis and rheumatism.

[36]  P. Aragona,et al.  Effects of the topical treatment with NSAIDs on corneal sensitivity and ocular surface of Sjögren's syndrome patients , 2005, Eye.

[37]  J. Whitcher,et al.  Lamivudine is not effective in primary Sjögren’s syndrome , 2005, Annals of the rheumatic diseases.

[38]  M. Dougados,et al.  Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases , 2004, Annals of the rheumatic diseases.

[39]  L. LaVange,et al.  Double-Masked, Placebo-Controlled Safety and Efficacy Trial of Diquafosol Tetrasodium (INS365) Ophthalmic Solution for the Treatment of Dry Eye , 2004, Cornea.

[40]  A. Tzioufas,et al.  Primary Sjögren’s syndrome: new clinical and therapeutic concepts , 2004, Annals of the rheumatic diseases.

[41]  J. Chodosh,et al.  A randomized, double-masked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5%, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance. , 2004, American journal of ophthalmology.

[42]  S. Pillemer,et al.  Pilot clinical trial of dehydroepiandrosterone (DHEA) versus placebo for Sjögren's syndrome. , 2004, Arthritis and rheumatism.

[43]  T. Medsger,et al.  Successful Treatment of Dry Mouth and Dry Eye Symptoms in Sjögren's Syndrome Patients With Oral Pilocarpine: A Randomized, Placebo-Controlled, Dose-Adjustment Study , 2004, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

[44]  K. Tsubota,et al.  Therapeutic effect of cevimeline on dry eye in patients with Sjögren's syndrome: a randomized, double-blind clinical study. , 2004, American journal of ophthalmology.

[45]  S. Pillemer,et al.  Etanercept in Sjögren's syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial. , 2004, Arthritis and rheumatism.

[46]  H. Moutsopoulos,et al.  Clinical manifestations and early diagnosis of Sjögren syndrome. , 2004, Archives of internal medicine.

[47]  S. Pillemer,et al.  Prominent adverse effects of thalidomide in primary Sjögren's syndrome. , 2004, Arthritis and rheumatism.

[48]  G. Baron,et al.  Inefficacy of infliximab in primary Sjögren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjögren's Syndrome (TRIPSS). , 2004, Arthritis and rheumatism.

[49]  P. Voulgari,et al.  Oral pilocarpine for the treatment of ocular symptoms in patients with Sjögren’s syndrome: a randomised 12 week controlled study , 2003, Annals of the rheumatic diseases.

[50]  E. Varnell,et al.  The comparison of efficacies of topical corticosteroids and nonsteroidal anti-inflammatory drops on dry eye patients: a clinical and immunocytochemical study. , 2003, American journal of ophthalmology.

[51]  G. Kammer,et al.  Treatment of primary Sjögren's syndrome with low-dose human interferon alfa administered by the oromucosal route: combined phase III results. , 2003, Arthritis and rheumatism.

[52]  C. Kallenberg,et al.  Treatment of primary Sjögren's syndrome with D-penicillamine: a pilot study. , 2002, The Netherlands journal of medicine.

[53]  E. Tindall,et al.  Cevimeline for the treatment of xerostomia in patients with Sjögren syndrome: a randomized trial. , 2002, Archives of internal medicine.

[54]  Stanley B. Cohen,et al.  A double-blind, randomized, placebo-controlled study of cevimeline in Sjögren's syndrome patients with xerostomia and keratoconjunctivitis sicca. , 2002, Arthritis and rheumatism.

[55]  R. Kiss,et al.  Infliximab in patients with primary Sjögren's syndrome: a pilot study. , 2001, Arthritis and rheumatism.

[56]  B. Reis,et al.  Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. The Cyclosporin A Phase 2 Study Group. , 2000, Ophthalmology.

[57]  B. Reis,et al.  Efficacy and safety of cyclosporin a ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: A dose-ranging, randomized trial☆ , 2000 .

[58]  B. Reis,et al.  Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group. , 2000, Ophthalmology.

[59]  B. Reis,et al.  Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease1 , 2000 .

[60]  S. Miyawaki,et al.  Efficacy of low-dose prednisolone maintenance for saliva production and serological abnormalities in patients with primary Sjögren's syndrome. , 1999, Internal medicine.

[61]  T. Appelboom,et al.  Zidovudine in primary Sjögren's syndrome. , 1999, Rheumatology.

[62]  M. Yaron,et al.  Hydroxychloroquine treatment for primary Sjögren’s syndrome: its effect on salivary and serum inflammatory markers , 1999, Annals of the rheumatic diseases.

[63]  S. Pflugfelder,et al.  Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjögren syndrome. , 1999, Ophthalmology.

[64]  F. Vivino,et al.  Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sjögren syndrome: a randomized, placebo-controlled, fixed-dose, multicenter trial. P92-01 Study Group. , 1999, Archives of internal medicine.

[65]  P. Venables,et al.  A double blind placebo controlled trial of azathioprine in the treatment of primary Sjögren's syndrome. , 1998, The Journal of rheumatology.

[66]  K. Shiozawa,et al.  Single-blinded controlled trial of low-dose oral IFN-alpha for the treatment of xerostomia in patients with Sjögren's syndrome. , 1998, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[67]  H. Moutsopoulos,et al.  Methotrexate in primary Sjögren's syndrome. , 1996, Clinical and experimental rheumatology.

[68]  R. Fox,et al.  Treatment of primary Sjögren's syndrome with hydroxychloroquine: a retrospective, open-label study , 1996, Lupus.

[69]  C. Bucca,et al.  Respiratory function in systemic lupus erythematosus: relation with activity and severity , 1996, Lupus.

[70]  A. van der Heide,et al.  Hydroxychloroquine treatment for primary Sjögren's syndrome: a two year double blind crossover trial. , 1993, Annals of the rheumatic diseases.

[71]  P. Fox,et al.  Prednisone and piroxicam for treatment of primary Sjögren's syndrome. , 1993, Clinical and experimental rheumatology.

[72]  M. Ramos-Casals.  EULAR Sjögren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjögren's syndrome , 2010 .

[73]  Atlanta,et al.  Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. , 2008, Arthritis and rheumatism.

[74]  L. V. D. van de Putte,et al.  Etanercept in the treatment of patients with primary Sjögren's syndrome: a pilot study. , 2004, The Journal of rheumatology.

[75]  A. V. Khurshudian.  A pilot study to test the efficacy of oral administration of interferon-alpha lozenges to patients with Sjögren's syndrome. , 2003, Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics.

[76]  A. Drosos,et al.  Cyclosporin a therapy in patients with primary Sjögren's syndrome: results at one year. , 1986, Scandinavian journal of rheumatology. Supplement.

[77]  C. Ward,et al.  A double-blind, cross-over, study of oral N-acetylcysteine in Sjögren's syndrome. , 1986, Scandinavian journal of rheumatology. Supplement.